Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Date:10/1/2008

expected to cause residual sedative effects the next morning if used in the middle of the night with less than eight hours of time remaining in bed. The rapidly absorbed, lower zolpidem dose used in Intermezzo(R) has been developed to treat middle of the night awakenings, to be taken as needed at the time they occur.

Intermezzo(R) (zolpidem tartrate sublingual lozenge) employs the proprietary Transcept Bimucoral(R) technology in a mint-flavored, sublingual lozenge formulated to dissolve under the tongue in approximately two minutes. A bioavailability study has demonstrated that, despite the fact that Intermezzo(R) 3.5 mg contains only about one-third the dose of zolpidem as compared to an Ambien(R) 10 mg tablet, Intermezzo(R) achieved significantly higher overall bioavailability in the first 10 to 20 minutes after administration when compared to the higher Ambien(R) dose.

About the Proposed Transcept and Novacea Merger

On September 2, 2008, Transcept Pharmaceuticals, Inc. and Novacea, Inc. (Nasdaq: NOVC) entered into a definitive merger agreement under which Novacea will merge with Transcept in an all-stock transaction. Further information on the merger agreement is available in the last section of this press release, entitled "Additional Information about the Merger and Where to Find It."

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomn
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Partners announced today that it has updated coverage ... Analyst at Vista Partners stated, "Raptor is potentially a ... balanced pipeline of clinical and preclinical programs.  The Company ... and one Phase 3 trial with some indications in ...
... Sept. 15 Masimo (Nasdaq: ... of Health, Labor and Welfare (MHLW) regulatory clearance ... available as part of the Masimo rainbow SET® ... continuously measuring a patient,s hemoglobin level in real-time, ...
Cached Medicine Technology:Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 2Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 3Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan 4
(Date:7/9/2014)... is for more than watching World Cup highlights, Brian ... skateboarders landing in unfortunate positions on railings. A University ... Dermatology Online Journal shows that YouTube also allows ... the public on topics of skin cancer and prevention. ... is the future of how we communicate around the ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... A study published in the scientific journal Nature ... two researchers at Universit Laval, reveals that it is ... that involves rekindling pain so that it can subsequently ... to alleviate chronic pain. , The researchers from the ... en sant mentale de Qubec (IUSMQ) were inspired by ...
(Date:7/8/2014)... Program in Memory Restoration has been awarded up to ... (DARPA) for a four -year project aiming to help ... of experts in neurosurgery, engineering, neurobiology, psychology and physics ... memory prosthesis in the brain. , Memory is the ... brain encode information, store it and retrieve it. Certain ...
(Date:7/8/2014)... In a study published yesterday in the scientific journal ... Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes ... over 200 million people world wide. , An organism,s ... into small sections or ,neighborhoods., Scientists can determine which ... gene production, by looking for a marker on the genome ...
Breaking Medicine News(10 mins):Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... smokers say they,are likely to quit smoking because it is ... researchers. , The study, published Tuesday ... researchers looked at the smoking behaviors,of people who own or ... lived with a dog, cat or bird. , ...
... panel of pain-management experts representing the American Pain Society ... Pain Medicine (AAPM) has published the first comprehensive clinical ... pain medications for patients with chronic non-cancer pain. ... The Journal of Pain , www.jpain.org , ...
... PARI Respiratory Equipment launched two updated continuing ... with seven classes for respiratory therapists, nurses, case ... as group programs that are pre-approved for continuing ... Certification (CCMC), American Association of Respiratory Care (AARC), ...
... of Bio-IT World magazine, today announced the launch of a ... enterprise --www.ecliniqua.com. , ... Needham, MA ... publisher of Bio-IT World magazine, today announced the launch of ...
... use a new, cutting edge diagnostic technology to ... outcomes.WOBURN, Mass. and VEDBAEK, Denmark, Feb. 10 AdvanDx ... Rockford, Illinois has implemented AdvanDx,s PNA FISH(R) tests ... earlier than conventional methods to help their physicians, ...
... WESTFORD, Mass., Feb. 10 Cynosure, Inc. (Nasdaq: ... a broad array of light-based aesthetic treatment systems, today ... ended December 31, 2008. Fourth-Quarter 2008 Financial Results ... the three months ended December 31, 2008 were $25.5 ...
Cached Medicine News:Health News:Smokers Likely to Quit for Fido's Health, Not Their Own 2Health News:New guidelines for prescribing opioid pain drugs published 2Health News:New guidelines for prescribing opioid pain drugs published 3Health News:New guidelines for prescribing opioid pain drugs published 4Health News:PARI Respiratory Equipment Launches 2 New Continuing Ed Classes 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 3Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 2Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 4Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 5Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 6Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 7Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 8Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 9Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 10Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 11Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 12Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 13
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: